Filter by:

Reset Filter
  • Life Sciences
Showing 1 - 12 of 28
Case

Federal Trade Commission v. 1-800 Contacts

The Second Circuit Court of Appeals overturned an FTC decision regarding trademark enforcement against online competitors.

Case

Alleged Failure to Disclose Drug Safety Issues

Cornerstone Research was retained by a pharmaceutical company facing securities litigation after it withdrew a drug from the market because of safety concerns.

Case

ICC Arbitration Involving Commercially Reasonable Efforts to Develop and Commercialize a Drug

An ICC arbitration tribunal determined that the claimant did not materially breach its license agreement with the respondent, leaving the agreement in full effect.

Case

In re Niaspan Antitrust Litigation

The judge denied class certification in this pharmaceutical pay-for-delay multidistrict litigation.

Case

In re Intuniv Antitrust Litigation

The judge denied class certification in this pharmaceutical pay-for-delay case brought by a class of indirect purchasers.

Case

Cigna’s Acquisition of Express Scripts

The parties completed a $67 billion merger after receiving clearance from the U.S. Department of Justice and state departments of insurance.

Case

Hsu et al. v. Puma Biotechnology Inc. et al.

Positive jury verdict in rare securities class action trial.

Case

Product Hopping

Pharmaceutical manufacturers have been accused of engaging in product hopping by introducing modified versions of branded drugs nearing patent expiry while simultaneously withdrawing the older drugs to hinder generic substitution.

Case

Sampling In FCA Litigation

Clients draw on Cornerstone Research's statistical expertise to evaluate sampling analyses performed by opposing parties to prove liability and damages in False Claims Act litigation.

Case

Joint Development Marketing Dispute

Cornerstone Research worked with a life sciences competition expert in a dispute between two pharmaceutical companies that jointly developed a drug.

Case

Allergan Takeover Bid

Cornerstone Research worked with two experts who testified on Rule 14e-3 allegations that a hedge fund violated federal securities law on disclosures in cash tender offers.

Case

Alleged Theft of Trade Secrets for a Drug in Development

Professor Sean Nicholson and Cornerstone Research analyzed the loss in value of a drug in development due to the advantage that the manufacturer of a competing drug in development obtained…

How can we help you?

If you are looking for additional case experience examples, contact us.